Results 21 to 30 of about 14,647 (219)
Monitoring the use of dabigatran etexilate for stroke prevention: compliance with renal function guidelines [PDF]
Journal of Primary Health Care, 2020 INTRODUCTIONDabigatran etexilate has become widely used in New Zealand, but information relating to when renal function monitoring is being undertaken is lacking.
Alesha J. Smith +3 more
doaj +2 more sources
Optimizing the dose of dabigatran etexilate [PDF]
British Journal of Clinical Pharmacology, 2012 The benefit : risk ratio for an oral anticoagulant is crucial, since the consequences of thromboembolic events on the one hand, and intra- or extra-cranial haemorrhage on the other, are potentially very serious. Therefore, the target profile for any new oral anticoagulant should include ‘readily predictable dosage’.
John Posner
openalex +4 more sources
Safety of dabigatran etexilate for the secondary prevention of venous thromboembolism in children.
Blood, 2020 This open-label, single-arm, prospective cohort trial is the first phase 3 safety study to describe outcomes in children treated with dabigatran etexilate for secondary venous thromboembolism (VTE) prevention. Eligible children aged 12 to
Brandão LR +18 more
europepmc +2 more sources
An Unusual Side Effect of Dabigatran Etexilate Use - Acute Renal Failure
Eurasian Journal of Emergency Medicine, 2019 Dabigatran etexilate is a prodrug with anticoagulant effect through inhibition of thrombin. Although it does not require laboratory monitoring and has minimal food-drug interaction, its disadvantages are bleeding, common GIS-related side effects and the ...
Ekim Sağlam Gürmen, Adnan Bilge
doaj +2 more sources
Effects of Long-term Thrombin Inhibition (Dabigatran Etexilate) on Spontaneous Thrombolytic Activity during the Progression of Atherosclerosis in ApoE-/--LDLR-/- Double-Knockout Mice. [PDF]
Korean Circ J, 2020 Background and Objectives Atherosclerosis is characterized by a hypercoagulable state, during which coagulation and fibrinolytic factors are activated simultaneously.
Sanda T +4 more
europepmc +2 more sources
Рациональная фармакотерапия в кардиологии, 2016 Application of dabigatran etexilate for prevention of cardioembolic complications in nonvalvular atrial fibrillation is considered. Results of randomized clinical trials on efficacy and safety of dabigatran in various doses are discussed.
I. S. Yavelov
doaj +3 more sources
Российский кардиологический журналAim. To study the comparative pharmacokinetics and confirmation of bioequivalence of the generic (T) and original (R) dabigatran etexilate in healthy volunteers after a single oral dose under fasted conditions.Material and methods.
V. B. Vasilyuk +6 more
doaj +2 more sources
Dabigatran etexilate: a direct thrombin inhibitor
Italian Journal of Medicine, 2013 BACKGROUND Direct Thrombin Inhibitors (DTIs) represent a new and promising class of anticoagulants. Unlike heparin, they directly interact with thrombin and block fibrinogen binding.
M. Dugnani
doaj +5 more sources
Hemopericardium and Cardiac Tamponade in a Patient Treated with Dabigatran Etexilate. [PDF]
Korean Circ J, 2016 Dabigatran etexilate is one of the new oral anticoagulants approved to reduce the risk of stroke in patients with atrial fibrillation (AF). A variety of bleeding complications with dabigatran have been reported, but reports of hemopericardium are rare.
Kızılırmak F +5 more
europepmc +5 more sources